Skip to main content
Figure 3 | Journal of Hematology & Oncology

Figure 3

From: The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner

Figure 3

Cells treated with HB22.7 followed by bortezomib demonstrate increased ROS generation. Ramos cells were treated with hydrogen peroxide, bortezomib, HB22.7, or both bortezomib and HB22.7 (concurrently or sequentially) as shown in Figure 1a and described in Materials and Methods. Treatments are listed on the X-axis. ROS levels were assessed by flow cytometry and are presented as the fold increase in MFI (mean fluorescence intensity) compared to control (untreated) cells. Results shown are the average of three experiments. Error bars = SEM. (*) = p-value < 0.05 against all other treatment groups.

Back to article page